Photodynamic Therapy News and Research

RSS

USPTO confirms validity of DUSA's key Levulan PDT patent

DUSA Pharmaceuticals, Inc.®, a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT), today announced that the United States Patent and Trademark Office (USPTO) has completed its re-examination of US Patent No. 5,079,262, "Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid."

24 Jun 2010

Light therapy may be alternative treatment for prostate cancer

Cliff Berkman is working on a better way—one that specifically targets prostate cancer cells and causes a type of natural death that spares surrounding tissues from damage.

3 Jun 2010

Valocor Therapeutics acquires, licenses dermatology therapeutic programs from QLT

Valocor Therapeutics, Inc., a newly formed company focused on the development of innovative therapies for the treatment of dermatologic conditions, today announced the acquisition and license of certain dermatology therapeutic programs from QLT Inc.. This transaction was facilitated by a seed financing for Valocor led by the Working Opportunity Fund, which is managed by GrowthWorks Capital Ltd.

25 May 2010

Quest PharmaTech net consolidated loss for 2010 increases to $517,799

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced financial and operational results for the fiscal year ended January 31, 2010.

20 May 2010

CEA-Leti launches TARGET-PDT project to increase effectiveness of PDT for treating cancer

CEA-Leti today announced the launch of the TARGET-PDT project designed to increase the effectiveness of photodynamic therapy for treating cancer by developing a novel nano carrier-based approach.

12 May 2010

Quest initiates dosing in Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced the dosing of the first patient under the Company's recently initiated Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients. The study will evaluate the localization, safety, tolerability and preliminary treatment response of SL052 photodynamic therapy in 18 patients with localized prostate cancer.

12 May 2010

DUSA Pharmaceuticals first-quarter total product revenues up 22%

DUSA Pharmaceuticals, Inc., a dermatology company that is developing and marketing Levulan Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, reported today its corporate highlights and financial results for the first quarter ended March 31, 2010.

11 May 2010

DUSA Pharmaceuticals receives notice of allowance for patent covering blue light technology

DUSA Pharmaceuticals, Inc.®, a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT), today announced that the United States Patent and Trademark Office has issued a notice of allowance for a key patent related to its proprietary PDT light source, the BLU-U®, Blue Light Photodynamic Therapy Illuminator.

7 May 2010

DUSA Pharmaceuticals to unveil BLU-U Blue Light Photodynamic Therapy Illuminator at AAD meeting

DUSA Pharmaceuticals, Inc.®, a specialty pharmaceutical company focused on dermatology, will unveil an ergonomically enhanced BLU-U® Blue Light Photodynamic Therapy Illuminator at this year's American Academy of Dermatology meeting in Miami, Florida, March 5-9. BLU-U, in conjunction with the Levulan® Kerastick® topical treatment, is an integral part of the Levulan® Photodynamic Therapy (PDT) technology platform.

5 Mar 2010

Proper diagnosis, treatment and good skin care help control acne and rosacea

Acne and rosacea are two seemingly different skin conditions that have one important thing in common: both are chronic and extremely common skin conditions. However, dermatologists recommend that with proper diagnosis, treatment and a healthy dose of good, old-fashioned skin care, acne and rosacea can be less of a nuisance for patients.

5 Mar 2010

Fluorescence method predicts the efficacy of PDT for Port Wine Stains: Study

It is known that fluctuations in the treatment outcome of photodynamic therapy (PDT) between patients are related to the concentration of photosensitizer in target tissue. The purpose of a study, by Wang et al, published in the February 2010 issue of Experimental Biology and Medicine was to establish a fluorescence method not only providing a semi-quantitative measurement of photosensitizer concentration but also predicting the efficacy of PDT for Port Wine Stains (PWS).

2 Mar 2010

Photocontrolled molecular switch regulates paralysis in animals

In an advance with overtones of Star Trek phasers and other sci-fi ray guns, scientists in Canada are reporting development of an internal on-off "switch" that paralyzes animals when exposed to a beam of ultraviolet light. The animals stay paralyzed even when the light is turned off. When exposed to ordinary light, the animals become unparalyzed and wake up.

4 Feb 2010

PhotoMedex, Galderma Laboratories enter into co-promotion agreement for photodynamic therapy application

PhotoMedex and Galderma Laboratories, L.P. have entered into a co-promotion agreement for Galderma’s photodynamic therapy application for the treatment of actinic keratoses (“AK”).

11 Jan 2010

Novartis presents 6-month results from its EVEREST study for PCV

QLT Inc. welcomed the 6-month results from the Novartis-sponsored EVEREST study which were presented during a scientific review today by Novartis in Basel, Switzerland.

9 Dec 2009

New photocontrolled molecular switch regulates paralysis in living organisms

19 Nov 2009

Press conference highlights emerging treatments in pancreatic cancer

As part of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Thompson will moderate a press conference on emerging treatments in pancreatic cancer on Tuesday, Nov. 17, 2009, in Room 202 of the Hynes Convention Center in Boston, Mass., from 1:00 p.m. to 2:00 p.m. ET.

18 Nov 2009

Levulan PDT may reduce the rate of recurrence of SCCs in solid organ transplant recipients: Study

The results of an independent investigator study just published in the online version of Dermatologic Surgery demonstrate that Levulan(®) Photodynamic Therapy (PDT) may reduce the rate of recurrence of squamous cell carcinomas (SCCs) in solid organ transplant recipients (SOTRs), a population with a high incidence of nonmelanoma skin cancer.

10 Nov 2009

Global sales volumes of Levulan Kerastick exceed one million units

DUSA Pharmaceuticals, Inc.®, a specialty pharmaceutical company focused on dermatology, announced today that global sales volumes of the Levulan® Kerastick®, an integral part of the Levulan® Photodynamic Therapy (PDT) technology platform, surpassed one million units.

28 Oct 2009

Third-quarter fiscal 2009 results announced by QLT

QLT Inc. today reported financial results for the third quarter ended September 30, 2009.

27 Oct 2009

QLT to repurchase common shares on NASDAQ and Toronto Stock Exchange

QLT Inc. ("QLT" or the "Company") today announced that its board of directors has authorized the repurchase of up to 5% of QLT's outstanding common shares ("Common Shares") over the next 12 months on the NASDAQ Stock Market ("NASDAQ") and the Toronto Stock Exchange ("TSX"), pending required approvals.

27 Oct 2009